The authors concluded that pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1+, trastuzumab-resistant, advanced, and HER2+ breast cancer [65]. The gene discussed is ERBB2; the disease is breast carcinoma.